TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03514680

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CIPN Assessment and Management Algorithm
Description: The revised algorithm incorporates evidence-based CIPN assessment and management strategies and standardized CIPN/pain patient-reported outcomes measures. In terms of processes, trained study staff will administer the screening questionnaires (e.g., PRO-CTCAE, 0 - 10 numerical rating scale of worst CIPN pain intensity) to consented patients before their clinician visit (e.g., in the waiting room). Following patient completion of the screening questionnaires, study staff will provide the clinicians with a color-coded summary of the patients' responses to the screening questionnaires and the CIPN assessment and management algorithm. Clinicians may then use the algorithm at their discretion to guide the assessment and management of their patients' CIPN symptoms
Study: NCT05336825

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CO2 laser
Description: Mona Lisa CO2 laser

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine patch 5%
Description: lidocaine
Study: NCT05289583

Intervention type: BEHAVIORAL
Intervention: Dialectical Behavior Therapy
Description: DBT is a cognitive-behavioral treatment program that was developed to treat suicidal Patients with BPD (Linehan, 1993).
Study: NCT04551001

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cold forcep polypectomy
Description: Removal of appropriate polyps using cold forceps until no polyp visible under white light. Two additional biopsies performed at margins of polypectomy site.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cold snare polypectomy
Description: Removal of appropriate polyps using cold snare until no polyp visible under white light. Two additional biopsies performed at margins of polypectomy site.
Study: NCT04082910

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metoprolol
Description: Metoprolol was given in patients who received CAR T cell therapy for CRS control or CRS precaution.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metoprolol
Description: Metoprolol was given in patients who received CAR T cell therapy for CRS control or CRS precaution.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metoprolol, infliximab, etanercept, tocilizumab and/or other agents
Description: During the term of metoprolol use, antibodies (infliximab, etanercept and tocilizumab) and/or other agents were not completely limited to be used under the consideration of clinical requirement for sufficient control of continuously progressed CRS.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metoprolol, infliximab, etanercept, tocilizumab and/or other agents
Description: During the term of metoprolol use, antibodies (infliximab, etanercept and tocilizumab) and/or other agents were not completely limited to be used under the consideration of clinical requirement for sufficient control of continuously progressed CRS.
Study: NCT00966719

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lactation Consultant support
Description: Meeting with lactation consultant once while in hospital and up to 3 times after discharge, in addition to current standard of care for jaundice.
Study: NCT01842594

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus and hydroxychloroquine
Description: Both hydroxychloroquine 200 mg/tab and sirolimus 1 mg/tab are pills each are taken 2 tablet orally QD for 2 cycles .~Each treatment cycle is 28 days.
Study: NCT00682136

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: US-Guided Ropivacaine TAP Block
Description: Bilateral injection of local anaesthetic into the Transversus Abdominis plane, guided by ultrasound.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: US-Guided Ropivacaine TAP Block
Description: Bilateral injection of local anaesthetic into the Transversus Abdominis plane, guided by ultrasound.
Study: NCT03099941

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biofeedback
Description: The aim of this study is to investigate effects of a biofeedback application that is alternative to physical therapist feedback in core stabilization training of patients with CNLBP.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Biofeedback
Description: The aim of this study is to investigate effects of a biofeedback application that is alternative to physical therapist feedback in core stabilization training of patients with CNLBP.
Study: NCT00768404

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topirmate and Phentermine
Description: A single oral dose of the combination product VI-0521 (15 mg phentermine and 92 mg topiramate) will be administered with 240 mL of water at hour 0.
Study: NCT03230812

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carnitene (L-Carnitine or Levocarnitine)
Description: All subjects will undergo oral Carnitene (L-Carnitine or levocarnitine) supplementation for 96 days.The total dosage of L-carnitine per day will be 2970mg. Consumption of the chewing tablets will be divided over the day. Intake of these chewing tablets will be during breakfast (990mg), lunch (990mg) and during diner (990mg). Since the chewing tablets are only available in concentrations of 330mg, participants have to consume 3 chewing tablets per meal, a total of 9 chewing tablets each day.
Study: NCT03378089

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music Therapy
Description: No narcotic or anti-emetic therapy will be administered for at least 2 hours prior to music therapy session. Music therapy sessions will be administered by a board certified music therapist (MT-BC) and last approximately 45 minutes. Involvement in sessions will be based on therapist and patient availability.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: No Music Therapy
Description: Participants will fill the same 45 minute period in any way they choose; however, they will be asked to refrain from listening to recorded music during this time.
Study: NCT02106247

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1181181 high dose
Description: two tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1181181 low dose
Description: one tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: tablet
Study: NCT01776671

Intervention type: DRUG
Group type: OTHER
Intervention: Gralise
Description: Titration starting 300 mg/day up to 1800 mg/day over 2 weeks
Study: NCT03724656

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: acupuncture treatment
Description: TAES treatment 30 minutes before induction of anesthesia. Bilateral Neiguan（PC6）, bilateral Zusanli（ST36）and bilateral Hegu （LI4）point were selected by electroacupuncture stimulation apparatus (HANS G6805-2, Huayi Co, Shanghai, China).After Deqi, electroacupuncture stimulation apparatus is connected and maintained until the end of operation.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham acupuncture treatment
Description: Participants in the sham acupuncture group received shallow needling (0.30mm×25mm) at bilateral sham points(nonacupoints located 5cm beside acupoints, about 20mm). The control group was treated with non-acupoint shallow acupuncture method and the needling depth was less than 2 mm. At the same time, the manual stimulation and Deqi was avoided.
Study: NCT04214431

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Childbirth Education
Description: 8-week mindfulness-based childbirth education
Study: NCT00477269

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib mesylate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib mesylate
Study: NCT04183491

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Peginterferon beta-1a
Description: Peginterferon beta-1a 31.25 µg administered SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Peginterferon beta-1a
Description: Peginterferon beta-1a 62.5 µg administered SC
Study: NCT03414684

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin interferes with the development of the genetic material in a cell, which will cause the cancer cells to die.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin interferes with the development of the genetic material in a cell, which will cause the cancer cells to die.
Study: NCT02734446

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Reuterin D3 drops
Description: 5 drops/day for 3 months

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 5 drops/day for 3 months
Study: NCT04242615

Intervention type: OTHER
Intervention: Prognostic score

Intervention type: OTHER
Intervention: Prognostic score
Study: NCT04389567

Intervention type: DRUG
Intervention: Famotidine
Description: Use of oral Famotidine.
Study: NCT00477269

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04418336

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic Pilonidal sinus treatment (EPSIT) versus Sinus Laser Closure (SiLaC) versus lay open technique
Description: Endoscopic Pilonidal sinus treatment (EPSIT) versus Sinus Laser Closure (SiLaC) versus lay open technique in sacrococcygeal Pilonidal sinus treatment

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic Pilonidal sinus treatment (EPSIT) versus Sinus Laser Closure (SiLaC) versus lay open technique
Description: Endoscopic Pilonidal sinus treatment (EPSIT) versus Sinus Laser Closure (SiLaC) versus lay open technique in sacrococcygeal Pilonidal sinus treatment

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic Pilonidal sinus treatment (EPSIT) versus Sinus Laser Closure (SiLaC) versus lay open technique
Description: Endoscopic Pilonidal sinus treatment (EPSIT) versus Sinus Laser Closure (SiLaC) versus lay open technique in sacrococcygeal Pilonidal sinus treatment
Study: NCT02989051

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Restrictive fluid regimen
Description: In this treatment arm, patients will receive a maximal daily fluid intake of 70% of normal requirements (for a healthy child).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Liberal fluid regimen
Description: This is considered current standard clinical treatment, wherein patients will receive a fluid regimen of \>85% of normal fluid recommendations (for a healthy child).
Study: NCT03186391

Intervention type: OTHER
Intervention: Data collected
Description: Use the data collected during a usual consultation to study the relationship between different parameters (rest pressure ...) and imaging
Study: NCT05764031

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical pilates exercise
Description: Clinical pilates is an exercise modality in which postural muscles are worked out with various body movements, and involves multi-muscle synergies that improve spinal stabilization, flexibility and endurance.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Description: Aerobic exercise (also known as endurance activities, cardio or cardio-respiratory exercise) is physical exercise of low to high intensity that depends primarily on the aerobic energy-generating process.
Study: NCT02011490

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sugammadex
Description: sugammadex 4 mg/kg IV bolus

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sugammadex
Description: sugammadex 4 mg/kg IV bolus

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sugammadex
Description: sugammadex 4 mg/kg IV bolus

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sugammadex
Description: sugammadex 4 mg/kg IV bolus

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sugammadex
Description: sugammadex 4 mg/kg IV bolus

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sugammadex
Description: sugammadex 4 mg/kg IV bolus
Study: NCT04086446

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: high-definition transcranial direct current stimulation
Description: The tDCS device will deliver a direct current of 1.5mA during 20 minutes. Cathode electrode will be localized in front of the right OFC on the Fp2 point according to the EEG international reference. Four anode electrodes will be placed around FP2 (i.e. Fpz, AFz, AF4, AF8)

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham tDCS
Description: The same procedure will be applied except that the tDCS device will only deliver a current stimulation for the first and last 15 seconds.
Study: NCT03783104

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: B12 Supplement
Description: Differential doses of vitamin B 12 supplementation in a two-armed randomised controlled trial

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: B12 Supplement
Description: Differential doses of vitamin B 12 supplementation in a two-armed randomised controlled trial
Study: NCT01071356

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive MI
Description: Weekly individual therapy sessions over 9 weeks (Intensive MI condition) consisting of supportive and directive interventions. The control condition consists on a single session of MI and nutritional education.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Single session MI
Description: Comparator arm that includes 1.5 hours of MI, 8 hours of nutrition classes and outpatient substance abuse treatment
Study: NCT01653899

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDN-6556
Description: 14 day oral treatment of the investigational caspase inhibitor drug IDN-6556 following first islet transplant at 50mg twice daily.
Study: NCT04058704

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Icotinib
Description: 125mg Tid/375mg per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Icotinib
Description: 125mg Tid/375mg per day

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SRS/WBRT/HA-WBRT/SMART
Description: \>3 with WBRT/HA-WBRT/SMART or 1-3 with SRS

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SRS/WBRT/HA-WBRT/SMART
Description: \>3 with WBRT/HA-WBRT/SMART or 1-3 with SRS
Study: NCT02745847

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Re-irradiation with SBRT
Description: Patients previously treated with SBRT with relapsed pancreatic cancer will be re-irradiated with SBRT.
Study: NCT02621398

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 3-Dimensional Conformal Radiation Therapy
Description: Undergo 3D-CRT or IMRT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-Modulated Radiation Therapy
Description: Undergo 3D-CRT or IMRT

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study: NCT01605318

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Labetuzumab Govitecan (LG)
Description: Administered as a slow intravenous (IV) infusion.
Study: NCT04183491

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Peginterferon beta-1a
Description: Peginterferon beta-1a 125 µg administered SC

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (administered either IM or SC)
Study: NCT04602949

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Breath Biopsy Analysis
Description: Analysis of a single breath Biopsy
Study: NCT01605318

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Labetuzumab Govitecan (LG)
Description: Administered as a slow intravenous (IV) infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Labetuzumab Govitecan (LG)
Description: Administered as a slow intravenous (IV) infusion.
Study: NCT02337699

Intervention type: DEVICE
Intervention: Implantation with the commercially available Axium neurostimulator

Intervention type: DEVICE
Intervention: Implantation with the commercially available Axium neurostimulator

Intervention type: PROCEDURE
Intervention: QST Testing
Study: NCT02018874

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2780301
Description: LY2780301 will be given orally Q.D. at different dose levels. Because of a favourable safety profile, the different dose levels will be as follow :~* Dose level -1: 300 mg Q.D.~* Dose level -0.5: 400 mg Q.D.~* Dose level 1: 400 mg Q.D.~* Dose level 1.5: 500 mg Q.D.~* Dose level 2 : 500 mg Q.D.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: The dose level of Gemcitabine will be fixed (1000 mg/m2). Gemcitabine will be administered over a 30 minutes infusion.
Study: NCT03237130

Intervention type: PROCEDURE
Intervention: preoperative enhanced chest CT examination
Description: Each patient will receive preoperative enhanced chest CT examination, and their CT images will be used for analysis
Study: NCT03738007

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HA IDF II
Description: Treatment with HA IDF II (YVOIRE volume)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Perlane
Description: Treatment with Perlane
Study: NCT05749653

Intervention type: DRUG
Group type: OTHER
Intervention: Bi-annual CDTI
Description: Bi-annual CDTI
Study: NCT00837018

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: physical exercise program
Description: 45 min, 3times a week
Study: NCT01283490

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: DASD Group
Description: Single application of 20% Benzocaine applied for one minute with the DASD ultrasonic and sonic vibration prior to needle puncture.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sonic Vibration (SV)
Description: Single application of 20% benzocaine applied with SV for one minute prior to needle puncture.
Study: NCT04333342

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: heart rate monitoring using wearable devices
Description: Using Fitbit (TM) wearable devices, heart rate, activity data are collected. Based on these data, resting heart rate is monitored daily basis. If resting heart rate increase beyond set range, users are notified to visit the hospital.
Study: NCT02713516

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: Use of virtual reality to deliver exposure therapy
Study: NCT00143533

Intervention type: DRUG
Group type: OTHER
Intervention: Irinotecan, Cefpodoxime
Description: See Detailed description section for treatment details.
Study: NCT03927352

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SCT630
Description: Administered by subcutaneous injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab
Description: Administered by subcutaneous injection
Study: NCT03734068

Intervention type: DEVICE
Intervention: Chemoembolization Using LifePearl
Description: Chemoembolization Using LifePearl

Intervention type: DRUG
Intervention: Doxorubicin
Description: Doxorubicin is loaded to LIfePearl
Study: NCT03631212

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Flexiquit
Description: Digital avatar-led Acceptance and Commitment Therapy for smoking cessation
Study: NCT03315169

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: External dressing
Description: Application of external dressing whilst perianal abscess cavity heals.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Packing of perianal abscess cavity
Description: Internal packing of perianal abscess cavity - standard treatment.
Study: NCT00955604

Intervention type: DRUG
Intervention: Group R+AD Rasagiline + Antidepressant
Description: Rasagiline and an antidepressant (SRIs, SNRIs, St. John's wort and/or TCAs) at least 14 days

Intervention type: DRUG
Intervention: Group R Rasagiline
Description: At least 2 months of rasagiline

Intervention type: DRUG
Intervention: Group AD Anti-PD + Antidepressant
Description: An approved dopaminergic medication for PD. (2 months of treatment with an antidepressant medication.
Study: NCT02437786

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GRAZAX
Description: GRAZAX
Study: NCT02534662

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ENDOMINA
Description: Endomina will be introduced into the stomach over guide wires and then fixed to the endoscope. The procedure will include the placement of 4-6 transmural anterior-posterior sutures after argon plasma coagulation of the tissue opposition areas in order to ensure persistence of the pouch reduction. Patient will be kept overnight after the procedure.
Study: NCT00737594

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo capsules for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobiprostone
Description: Cobiprostone capsules for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobiprostone
Description: Cobiprostone capsules for oral administration
Study: NCT02739321

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sound to Sleep System
Description: Sound to Sleep System is a minimal risk device that is embedded in a mattress boxspring. The device syncs with an audio input and emits tactile vibrations in sync with the audio input.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sound to Sleep System
Description: Sound to Sleep System is a minimal risk device that is embedded in a mattress boxspring. The device syncs with an audio input and emits tactile vibrations in sync with the audio input.
Study: NCT01231815

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 15O-H2O PET -
Description: Assessment of coronary reserve using PET

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: MRI
Description: Assessment of coronary reserve using MRI
Study: NCT03414684

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab works by attaching to and blocking a molecule called PD-1. PD-1 is a different molecule that can turn off the immune system by interacting with PD-L1 on the cancer cells
Study: NCT01522612

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: 500 mg/m2 on day 1, Every 14 days Intravenously